Press release
Announce Strategic Partnership to Enhance Access to High-Quality Antibodies
Cambridge - August 28th 2025 - Antibodies.com, a trusted provider of high-quality antibodies and research reagents, is proud to announce a strategic partnership with Carl Roth, a leading supplier of laboratory and research chemicals. This collaboration represents an important milestone, expanding access to Antibodies.com's cutting-edge portfolio for Carl Roth's customers across Europe.Through this partnership, Carl Roth will distribute Antibodies.com's extensive collection of antibodies and immunoassays - including monoclonal, polyclonal, and recombinant products - designed to meet the needs of researchers in academia, biotechnology, and the pharmaceutical industry. With a strong reputation for quality, reliability, and affordability, Antibodies.com complements Carl Roth's mission to deliver best-in-class solutions for scientific discovery.
"We are excited to partner with Carl Roth, a company that shares our dedication to advancing scientific research," said Sebastian Newlove, Co-Founder of Antibodies.com. "Together, we aim to make high-quality antibodies more accessible, enabling researchers to achieve their goals with confidence and efficiency."
Dr. Leonie Hacker, Head of Product Management Chemistry & Life Science at Carl Roth, added: "This partnership represents a significant step forward in our commitment to empowering researchers with the best tools available. By integrating Antibodies.com's high-quality antibodies into our offerings, we are ensuring that our customers have access to innovative products at fair prices, supporting their groundbreaking work in life sciences."
Antibodies.com's customer-focused approach - emphasising transparency, rigorous quality control, and exceptional value - combined with Carl Roth's established distribution network, will streamline access to these products, ensuring seamless delivery and support for researchers across Europe.
This collaboration underscores the shared vision of both companies: to foster innovation and excellence within the scientific community. Researchers can now explore Antibodies.com's antibody portfolio through Carl Roth's online platform or by contacting their sales representatives for tailored support.
For more information about this partnership or to browse the expanded product offerings, visit www.antibodies.com [http://www.antibodies.com/?utm_source=chatgpt.com] or www.carlroth.com [http://www.carlroth.com/?utm_source=chatgpt.com].
About Carl Roth
Carl Roth, headquartered in Karlsruhe, Germany, is a leading distributor of laboratory supplies, chemicals, and equipment. With a legacy of excellence spanning decades, Carl Roth serves researchers and professionals in life sciences, chemistry, and beyond, delivering high-quality products and exceptional customer service.
About Antibodies.com
Antibodies.com is a global provider of high-quality antibodies and research reagents, dedicated to supporting scientific discovery. With a focus on affordability, reliability, and innovation, Antibodies.com empowers researchers with the tools they need to advance their work in immunology, oncology, and other critical fields.
Media Contact
Company Name: antibodies.com
Contact Person: Christian Lautenschlager
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=announce-strategic-partnership-to-enhance-access-to-highquality-antibodies]
Phone: + 44 (0)1223 298 875
Country: United Kingdom
Website: http://Antibodies.com
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Announce Strategic Partnership to Enhance Access to High-Quality Antibodies here
News-ID: 4162789 • Views: …
More Releases from ABNewswire
Acute Kidney Injury Market Insights Highlight Expanding Outlook Till 2034, Delve …
The Key Acute Kidney Injury Companies in the market include - Alloksys, Guard Therapeutics, Ocelot Bio, Angion Biomedica/Vifor Pharma AM Pharma, Astellas Pharma, Sentien Biotechnologies, RegeneRx Biopharmaceuticals, and others.
DelveInsight's "Acute Kidney Injury Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Acute Kidney Injury, historical and forecasted epidemiology as well as the Acute Kidney Injury market trends in the United States, EU4 (Germany, Spain, Italy, France)…
Octo Prints and Lighting Launches Custom Yard Signs With Nationwide Shipping
Octo Prints and Lighting launched custom yard signs on coroplast in three sizes (18x12, 24x18, 36x24) with single or double-sided CMYK printing and UV-resistant inks. Pricing starts at $19.50 with bulk discounts up to 70% off for 100+ units. Production takes 1-2 days. Designed for real estate, events, campaigns, contractors, and community use. H-stakes available. Orders ship nationwide via their website: https://decorativelightcovers.com/yard-signs/
LITHIA, Fla., United States - Jan 12, 2026 -…
Sjogren's Syndrome Market to Experience Notable Growth in Forecast Span by 2034, …
The Key Sjogren's syndrome Companies in the market include - Astellas Pharma, Immunovant Sciences, NK Cells Artiva Biotherapeutics, Rise Therapeutics, Bristol-Myers Squibb, Resolve Therapeutics, Novartis, Horizon Therapeutics, Dompe Farmaceutici, Horizon Therapeutics (Amgen), Sylentis, OSE Immunotherapeutics, Servier, Johnson & Johnson, and others .
DelveInsight's report "Sjogren's Syndrome Market Insights, Epidemiology, and Market Forecast-2034," provides a comprehensive analysis of the Sjogren's Syndrome landscape. The report delivers detailed insights into the disease, including historical…
Rich Noto, Realtor & Home Inspector Expands New Construction Services in Citrus …
Rich Noto, Realtor and licensed home inspector, is expanding new construction focused real estate services across Citrus Springs, Land O' Lakes, San Antonio, Weeki Wachee, and Spring Hill, Florida. Through his website, NewConstructionRealtor.Homes, Rich Noto provides prospective homeowner with detailed, location-specific information on new home communities, builders, and residential growth areas throughout Central Florida and Florida's Gulf Coast region.
Florida - As Florida continues to experience strong population growth, buyers are…
More Releases for Antibodies
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Arthritis Monoclonal Antibodies Market Report 2024 - Arthritis Monoclonal Antibo …
"The Business Research Company recently released a comprehensive report on the Global Arthritis Monoclonal Antibodies Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The arthritis monoclonal antibodies…
Global Multispecific Antibodies Market Size Antibodies Sales Forecast 2029
Global Multispecific Antibodies Market, Drug Sales, Price & Clinical Trials Insight 2029 Report Highlights:
• Global & Regional Market Analysis
• Global Multispecific Antibodies Market Opportunity: > USD 40 Billion
• Global Multispecific Antibodies Market Sales In 2023: > USD 8 Billion
• Number Of Approved Multispecific Antibodies: 14
• Approved Antibodies Global, Regional, Annual & Quarterly Sales Insight
• Approved Antibodies Dosage & Pricing Insight
• Number Of Multispecific Antibodies: In Clinical Trials: > 900
• Comprehensive Insight On All Antibodies In Clinical Trials By…
Global Bispecific Antibody Market Size Bispecific Antibodies Clinical Trials FDA …
Global Bispecific Antibody Market, Drugs Sales, Patent, Price and Clinical Trials Insight 2029 Report Highlights:
• Bispecific Antibodies Development Proprietary Platforms Insight: > 30 Platforms
• Global Bispecific Antibodies Market Size Yearly and Quarterly Sales (2018 till 2023)
• Global Bispecific Antibodies Market Size 2023: > USD 8 Billion
• Global Bispecific Antibodies Market Forecast Till 2029
• Approved Bispecific Antibodies Yearly and Quarterly Sales (2018 till 2023)
• Approved Bispecific Antibodies Regional Sales (2018 till 2023)
• Clinical and Commercial Insight On Approved…
Emergence of Tetravalent Antibodies
The emergence of tetravalent antibodies represents a significant advancement in the field of therapeutic antibodies, offering new possibilities for treating complex diseases such as cancer, infectious diseases, and autoimmune disorders. These innovative molecules, capable of binding to four antigens or epitopes simultaneously, provide enhanced specificity, efficacy, and versatility, addressing the limitations of traditional monoclonal and even bispecific antibodies.
Download Bispecific, Trispecific and Tetraspecific Antibodies Report:
https://www.kuickresearch.com/ccformF.php?t=1721642510
Tetravalent antibodies are designed to engage…
